ArticleMolecular medicine reports2018
Calotropin regulates the apoptosis of non‑small cell cancer by regulating the cytotoxic T‑lymphocyte associated antigen 4‑mediated TGF‑β/ERK signaling pathway.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Unveiling the therapeutic potential of Calotropis procera: from traditional applications to phytochemistry, pharmacology, and safety.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.Frontiers in immunology · 2024Review
- An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer.Frontiers in pharmacology · 2023Review
- Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4.Frontiers in oncology · 2020Article
- ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.International journal of molecular sciences · 2019Review
- Calotropin activates YAP through downregulation of LATS1 in colorectal cancer cells.OncoTargets and therapy · 2019Article
- Unveiling the anti-cancer mechanisms of calotropin: Insights into cell growth inhibition, cell cycle arrest, and metabolic regulation in human oral squamous carcinoma cells (HSC-3).Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non‑small‑cell lung cancer (NSCLC) is one of the most common malignancies that is responsible for a high level of cancer‑associated mortalities worldwide. Previous evidence has shown that Calotropin is an upstream activator of protein kinase B, which can further inhibit the growth and promote the apoptosis of NSCLC cells. In the present study, the efficacy of Calotropin on growth, aggressiveness and apoptosis of NSCLC cells was investigated, as well as the potential underlying mechanism. The results demonstrated that Calotropin inhibited H358 cell growth, migration and invasion. Flow cytometry assay showed that Calotropin promoted the apoptosis of H358 cells in vitro. Western blot analysis demonstrated that Calotropin inhibited fibronectin (FN), Vimentin (VIM) and E‑cadherin (Eca) protein expression levels in H358 cells in vitro. In addition, Calotropin treatment upregulated pro‑apoptosis gene expression, including caspase‑3, caspase‑8 and apoptotic protease activating factor‑1, and downregulated anti‑apoptosis gene expression, including P53, B‑cell lymphoma (Bcl) 2 and Bcl‑2‑like protein 2 in H358 cells. The results also revealed that the expression levels of cytotoxic T‑lymphocyte associated antigen 4 (CTLA‑4) were decreased by Calotropin treatment in H358 cells. Analyses of the underlying mechanism indicated that Calotropin inhibited transforming growth factor‑β (TGF‑β) and extracellular signal‑regulated kinase (ERK) expression. Overexpression of CTLA‑4 inhibited Calotropin‑mediated downregulation of TGF‑β and ERK expression in H358 cells. In vivo assay revealed that Calotropin administration significantly inhibited tumor growth and prolonged animal survival over the 120‑day observation period. Immunohistochemistry demonstrated that the number of apoptotic cells increased and the expression levels of CTLA‑4 were decreased in the Calotropin‑treated tumor group when compared with control. In addition, the expression levels of TGF‑β and ERK were downregulated in the Calotropin‑treated tumor group compared with control. In conclusion, the results of the present study indicated that Calotropin administration regulated NSCLC apoptosis by downregulating the CTLA‑4‑mediated TGF‑β/ERK signaling pathway, suggesting that Calotropin may be a potential anti‑cancer agent for the treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.